A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2013-07-09 / Clin. Cancer Res. 2013 Sep;19(17):4801-15Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2013-07-02 / Cancer Immunol. Immunother. 2013 Sep;62(9):1499-509Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2013-06-24 / J. Clin. Invest. 2013 Jul;123(7):3135-45Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy
/in Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus /von 2013-06-24 / Technol. Cancer Res. Treat. 2014 Apr;13(2):169-75Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme
/in Dendritic Cells, Glioblastoma, International Publications /von 2013-06-21 / Cancer Treat. Rev. 2013 Dec;39(8):891-907Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics
/in International Publications, Micronutrients /von 2013-06-19 / Antioxid. Redox Signal. 2013 Dec;19(17):2141-56A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2013-06-18 / J Transl Med 2013 Jun;11:149Biochemical and immunologic markers in patients with metastatic melanoma treated with chemotherapy and dendritic cell vaccine.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2013-06-04 / J Clin Oncol 31, 2013 (suppl; abstr e20042)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de